Interestingly, clinical outcome was correlated with the number of ex19del ctDNA copies in plasma as it disappeared within a few weeks from the beginning of osimertinib and appeared again and continuously improved thereafter, anticipating tumor progression
Interestingly, clinical outcome was correlated with the number of ex19delRead More